A
Adlai Nortye
Adlai Nortye engages in research and development of biopharmaceuticals for cancer immunotherapy
About Adlai Nortye
Adlai Nortye is a clinical-stage, global biopharmaceutical company with a dual presence in the United States and China, operating research and development as well as clinical operation centers in both countries. Founded in 2004, the company focuses on developing treatments for cancer through a strategy that combines in-house research with collaborative innovation. The company is led by founder, Chairman, and CEO, Lu Yang.
Adlai Nortye's business model is centered on the discovery, development, and commercialization of oncology therapies. It has established a pipeline of drug candidates targeting various cancers, aiming to address significant unmet needs in the global oncology market. The firm generates value by advancing these candidates through the rigorous phases of clinical trials, with the ultimate goal of obtaining regulatory approval and bringing new treatments to patients worldwide. Strategic partnerships with other leading pharmaceutical companies are a key component of its approach, enabling the co-development of promising therapies.
The company's product pipeline includes several candidates at different stages of clinical development. AN2025 (buparlisib), a PI3K inhibitor, has received Fast Track Designation from the FDA and is in a global Phase III trial. It is being studied in combination with paclitaxel as a potential second-line treatment for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) who have not responded to PD-1 inhibitors. Another key candidate is AN0025 (palupiprant), an EP4 antagonist designed to modulate the tumor microenvironment. It is currently in a Phase Ib trial in combination with Keytruda® for various solid tumors and a Phase II study with chemoradiotherapy for locally advanced cancers. Furthermore, Adlai Nortye is developing AN4005, an internally developed oral small molecule PD-L1 inhibitor, which is undergoing Phase I trials in both the U.S. and China. The company is also exploring a triple combination therapy using AN2025, AN0025, and Roche's Tecentriq for solid tumors with PI3KCA mutations.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VCOther financing | Apr 2026 | $150M | — | Casdin Capital · Perceptive Advisors · Kalehua Capital Management · Cormorant Asset Management | ↗ |
| PRIVATE PLACEMENT NON VCOther financing | Feb 2026 | $140M | — | Cormorant Asset Management · Balyasny Asset Management · Casdin Capital · Point72 | ↗ |
Growth signals
Latest recorded traffic for Adlai Nortye is 5.8K monthly website visits, up 48.7% over the last three months. Adlai Nortye's team grew 4.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Adlai Nortye in the Hangzhou ecosystem
The Adlai Nortye office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Matrix Partners China
Detong Capital- YCYuanMing Capital
Series B and later5 investors entered at this stage
Legend Star
Hangzhou Tigermed- CCCMG-SDIC Capital
Tigermed
WuXi Biologics
Other known investors10 additional known investors
Casdin Capital
Cormorant Asset Management
Squadron Capital Management
Balyasny Asset Management
Columbia Threadneedle Investments
Eventide Asset Management- KMKalehua Capital Management
Perceptive Advisors
Point72- SCSoleus Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Adlai Nortye on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Adlai Nortye’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










